New pill combo shows promise against tough breast cancer
NCT ID NCT04796623
First seen Apr 12, 2026 · Last updated Apr 28, 2026 · Updated 3 times
Summary
This study tested a new drug (TQB3616) combined with a standard hormone therapy (fulvestrant) in 122 people with advanced HR-positive, HER2-negative breast cancer. The goal was to see if the combination could shrink tumors or delay cancer growth. Participants had either received one prior treatment or none at all. The results help determine if this approach offers better disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830000, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
-
Gansu Provincial Hostipal
Lanzhou, Gansu, 730030, China
-
Guangdong General Hospital
Guangzhou, Guangdong, 510062, China
-
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, 530021, China
-
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110042, China
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200123, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510062, China
-
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100039, China
-
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, 710061, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
The Second Affiliated Hospital of PLA Air Force Military Medical University
Xi’an, Shanxi, 710038, China
-
The Second Hospital of Dalian Medical University
Dalian, Liaoning, 116027, China
Conditions
Explore the condition pages connected to this study.